A PHASE IIB TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF ONY-P VACCINES IN THE MANAGEMENT OF PROSTATE CANCER WITHOUT DETECTABLE METASTASES FOLLOWING INITIAL ESCAPE FROM HORMONE TREATMENT - THE TREATMENT OF ADVANCED PROSTATE CANCER USING DISABLED CANCER CELLS AS VACCINES

开始日期2006-10-16

申办/合作机构

Onyvax Ltd.

100 项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的临床结果

登录后查看更多信息

100 项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的转化医学

登录后查看更多信息

100 项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的专利（医药）

登录后查看更多信息

项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的文献（医药）

2005-10-01·Current opinion in molecular therapeutics

Technology evaluation: Onyvax-P, Onyvax.

Review

作者: Doehn, Christian ; Jocham, Dieter ; Böhmer, Torsten

Onyvax is developing Onyvax-P, an allogeneic whole-cell vaccine, for the potential treatment of prostate cancer. The vaccine is currently undergoing phase II clinical trials.

2003-12-01·Current opinion in molecular therapeutics

Technology evaluation: Onyvax-105, Onyvax.

Article

作者: Blumenthal, Rosalyn D

Onyvax, under license from the Cancer Research Campaign, is developing Onyvax-105 (105AD7), an anti-idiotype monoclonal antibody, for the potential treatment of colorectal cancer. Onyvax initiated phase II clinical trials in May 2000.

1978-01-01·Chemical and Pharmaceutical Bulletin4区 · 医学

Immune competence-promoting action of bovine parotid hypocalcemic factor obtained via extraction with glacial acetic acid.

4区 · 医学

Article

作者: Suzuki, Ikukatsu ; Nakamura, Tatsuko ; Adachi, Shigeru ; Mizutani, Akira ; Ohba, Yasuyo

The hypocalcemic substance P-MSY (mol. weight 66,000) and a few partially purified products obtained by HOAc extraction of bovine parotid extract were examined for immune adjuvanticity.The P-MSY (0.1 μg/mouse) produced a lymphocyte/polymorphonuclear leukocyte (L/P) ratio of 2.72, and the effect was significant at 1% against the control group.Plaque + rosette-forming cell (PFC and RFC) activities were significant at <5% level of significance against the resp. control group in a dose of 2.5 μg/mouse (PFC/10⁶ cells: 53.57, RFC/10⁶ cells: 13,854).The L/P activity of P-MSY was increased by ∼2000 times that of Me₂CO-dried powder PAI and starting materials, and the increases in PFC and RFC activities were both ∼80 times.Through the assay of P-MSY and partial purified products, a tendency to increase in L/P, PFC, and RFC activities was found in proportion to hypocalcemic activity.The regression of L/P and PFC activities against log doses were examined, and it was concluded that each response resolved linearly over a moderate range of doses.

100 项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
前列腺癌	临床2期	-	National Cancer Institute	-
前列腺癌	临床2期	-	Onyvax Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2005	临床2期	转移性前列腺癌	20	ONY-P1	(醖壓襯鹹遞壓鑰積廠築) = A statistically significant sustained PSA velocity reduction was seen in 3 patients (23%) 糧簾蓋壓觸淵壓築衊顧 (選鹹廠壓齋窪製鏇製積 )	-	2005-06-01